Please login to the form below

Not currently logged in
Email:
Password:

Pfizer/ Medivation AD drug fails trial

Pfizer and Medivation's Alzheimer's Disease treatment, Dimebon (latrepirdin), has failed to meet its efficacy endpoints in a phase III trial

Pfizer and Medivation's Alzheimer's Disease (AD) treatment, Dimebon (latrepirdin), has failed to meet its co-primary or secondary efficacy endpoints in a phase III trial.

The phase III, multi-national, double-blind, placebo-controlled ,CONNECTION trial, involved 598 patients with mild-to-moderate AD.

Dr David Hung, president and CEO of Medivation, said: "The results from the CONNECTION study are unexpected, and we are disappointed for the Alzheimer's community." 

He went on to say that Medivation would be working with Pfizer to analyse the data from the trial. 

Dr Briggs W Morrison, senior vice president, clinical development, Primary Care Business Unit at Pfizer said: "We recognise the significant medical need, and we are committed to advancing treatment options for Alzheimer's disease."

Both the CONNECTION study and a separate phase III study found Dimebon to be well tolerated when dosed alone or in combination with other approved AD therapies.

Dimebon is being studied in four other ongoing randomised, double-blind, placebo-controlled phase III studies, which currently are enrolling. 

Medivation and Pfizer have a global collaboration to develop and commercialise Dimebon for the treatment of Alzheimer's disease and Huntington's disease. Under the terms of the agreement, the companies work together on the Dimebon development programme.

4th March 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics